One-Third of Young Women With Breast Cancer Delay Care
By Lori Solomon HealthDay Reporter
MONDAY, April 15, 2024 -- A significant proportion of young women with breast cancer experience diagnostic delay, most often related to patient factors, according to a study presented at the annual meeting of the American Society of Breast Surgeons, held from April 6 to 10 in Orlando, Florida.
Katherine Fleshner, M.D., from the University of Calgary in Alberta, Canada, and colleagues evaluated the diagnostic timeline among a cohort of women aged 40 years and younger with breast cancer and identified predictors of diagnostic delay. The analysis included 1,148 patients followed for five years.
The researchers found that 36.8 percent of participants also had a first-degree relative with cancer. Most patients (89.0 percent) had a symptom prompting assessment, including, most commonly, a palpable mass (77.3 percent). Patients reported waiting a median of two weeks before seeking care, with one-third of participants experiencing a patient delay. Lack of concern, waiting a menstrual cycle, reassurance by another practitioner, difficulty accessing care, and competing priorities were reasons given for patient delays. Having a painful lump as the presenting symptom and having a first-degree relative with breast cancer were independent predictors of patient delay. In contrast, 10.1 percent of participants experienced a system delay. There were no independent predictors of system delay identified.
"Premenopausal breast cancer is uncommon, but accelerating the diagnostic timeline is extremely important," Fleshner said in a statement.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted April 2024
Read this next
ACG: 2000 to 2022 Saw Rise in Early-Onset CRC Mortality in the United States
THURSDAY, Oct. 31, 2024 -- Early-onset colorectal cancer (EO-CRC) mortality rose in the United States over the past two decades, most notably in patients aged 20 to 44 years...
Inavolisib + Palbociclib-Fulvestrant Improves Survival in Advanced Breast Cancer
THURSDAY, Oct. 31, 2024 -- Inavolisib plus palbociclib-fulvestrant yields significantly longer progression-free survival than placebo plus palbociclib-fulvestrant in patients with...
Cell-Free Blood DNA Tests Less Effective Than Other CRC Screening
WEDNESDAY, Oct. 30, 2024 -- Cell-free DNA blood tests (cf-bDNA) may be more costly and less effective for colorectal cancer (CRC) screening than other screening modalities...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.